OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

Novel PI3K Inhibitors in B-Cell Malignancies

home / insights / pi3k-inhibitors-bcell
Advertisement
Treating Chronic Lymphocytic Leukemia

EP. 1: Treating Chronic Lymphocytic Leukemia

June 29th 2016
Role of PI3K-Targeted Therapy in CLL

EP. 2: Role of PI3K-Targeted Therapy in CLL

June 29th 2016
Duvelisib in Relapsed/Refractory CLL

EP. 3: Duvelisib in Relapsed/Refractory CLL

June 29th 2016
Encouraging Early Data for Novel PI3K Inhibitors

EP. 4: Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016
Treatment of Follicular Lymphoma

EP. 5: Treatment of Follicular Lymphoma

June 29th 2016
PI3K-Targeted Therapy for Follicular Lymphoma

EP. 6: PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016
Advertisement
Preliminary Data for Duvelisib in Indolent NHL

EP. 7: Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016

Latest Conference Coverage

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact